Intractable Atrial Flutter Successfully Treated with Flecainide and Propranolol in a Premature Infant

Min Ju Lee, Se Hwan Ahn, Jong Han Kim, Su Yeong Kim, Ji-Eun Ban

Department of Pediatrics, Hallym University Kangdong Sacred Heart Hospital, 1Department of Pediatrics, Ewha Womans University School of Medicine, Seoul, Korea

Introduction

Neonatal atrial flutter (AFL) has a usually benign clinical course in patients with normal structural hearts. However, an AFL can be potentially lethal in cases of recurrent attack and can result in complications, such as congestive heart failure. Moreover, an intractable AFL requires multiple external electrical cardioversions, and it shows a poor response to antiarrhythmic drug therapy. We report a case of a premature infant with an intractable AFL, which we successfully treated with oral flecainide and propranolol in spite of recurrent AFL.

Case

A 1-month-old, 34-week gestation, premature baby presented with an irregular heart beat and irritability. An AFL with 2:1 atrioventricular conduction was documented. Because of the intractable AFL, repeated electrical cardioversion and amiodarone were continued for 14 days. However, amiodarone was discontinued in favour of flecainide and propranolol because of the recurrent AFL and newly developed transient hypothyroidism. During 1-year follow-up period, in which oral flecainide and propranolol were continued, no AFL was observed. (Ewha Med J 2017;40(3):140-142)
Adenosine was administered, and an AFL was observed with variable atrioventricular conduction at an atrial rate of 300 beats/min (Fig. 2B). Although electrical cardioversion (1 J/kg) terminated the AFL, the intravenous loading of amiodarone was infused, and then a maintenance dose of oral amiodarone was administered because of the intractable AFL. While remain normal sinus rhythm, frequent APCs were seen. On day 14, the AFL with 2:1 atrioventricular conduction recurred. Synchronized electrical cardioversion was performed, and sinus rhythm was restored. A non-conducted APC was frequently observed on the electrocardiogram telemetric monitoring. Moreover, the neonate developed transient hypothyroidism. Therefore, amiodarone was
discontinued on day 17, and oral flecainide and propranolol were simultaneously administered. After titration of propranolol over 7 days and flecainide over 8 days, we reached the therapeutic range of flecainide (5 mg/kg/day) and propranolol (3 mg/kg/day). And no more APCs were observed over 10 days. Following an increased dosage of flecainide and propranolol, there was no AFL recurrence. However, the infant suffered from respiratory syncytial viral infection. Because of the underlying laryngomalacia with a co-pulmonary infection, he required ventilator support. Despite prolonged hospital stays under respiratory care, the infant did not demonstrate AFL or an APC. The neonate was discharged with oral flecainide and propranolol therapy on day 34. During 1 year of chronic oral antiarrhythmic therapy, there was no recurrence of AFL. In addition, no proarrhythmic side effects were documented. And he has been free of AFL during the 10-month follow-up period without antiarrhythmic medication.

**Discussion**

In this report, we presented a case of a premature infant with an intractable AFL, which we initially treated with repeated electrical cardioversion and intravenous amiodarone, but this treatment did not demonstrate strong control of the condition. Under oral amiodarone maintenance therapy, a recurrent AFL occurred, and transient hypothyroidism developed. After substituting the amiodarone with other combination therapy (i.e., flecainide and propranolol), the intractable AFL was suppressed. In this case, frequent APC probably as the trigger for the recurrence of the AFL. Baseline surface electrocardiography demonstrated frequent APCs with aberrant conduction or non-conduction prior to AFL occurrence. In addition, APCs were frequently seen whenever AFL was terminated. Finally, AFL was not recurred after controlled APCs with flecainide and propranolol. We assumed that atrial ectopy may lead to the initiation of reentrant mechanism of AFL.

Prior studies have shown that electrical cardioversion and intravenous use of antiarrhythmic drugs therapy, such as amiodarone, propafenone, and flecainide, are usually the most effective therapy for the acute termination of neonatal AFL [4,5]. Only a few case reports have investigated using antiarrhythmic drug therapy to treat intractable AFL in a premature baby [6,7]. Flecainide is a class IC antiarrhythmic drug that act primarily slows conduction by depressing the maximum rate of the rise of depolarization of the action potential with minimal prolongation of refractoriness. And propranolol is a non-selective beta blocker with atioventricular node blocking. Perhaps the flecainide and propranolol helped suppress these. There is much good evidence that oral combination therapy with a class IC antiarrhythmic drug combined with a beta blocker is effective at suppressing intractable AFL in a premature infant. To our knowledge, in the literature, there are no case reports in which a premature infant was successfully treated with oral flecainide and propranolol without any proarrhythmic side effects. Therefore, these combination therapies may be considered to an effective therapy in this special clinical setting.

**References**